Ariad Pharmaceuticals | search
Click here to view Ariad Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited (“Takeda”) today announced the completion of its acquisition of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) (“ARIAD”) for $24.00 per share in cash. “We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals.
- Japan’s Takeda to acquire US cancer drug manufacturer ARIAD for $5.2bnJapanese-based Takeda Pharmaceutical Company has signed an agreement to acquire American oncology company ARIAD Pharmaceuticals for approximately $5.2bn. With the acquisition of ARIAD, Takeda will gain access to the leukaemia drug Iclusig, as well as new lung cancer treatment drug Brigatinib.
- Takeda is buying Ariad Pharmaceuticals in a $5.2 billion dealThe Japanese pharmaceutical company Takeda is buying the Cambridge, Massachussets-based Ariad Pharmaceuticals for $24 a share. The deal, valued at about $5.2 billion, is expected to close in...
- Takeda to Acquire ARIAD Pharmaceuticals, Inc.ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers.
- Takeda shells out whopping $5.2B for Ariad, Iclusig and its fledgling ...In a deal valued at $5.2 billion, Takeda plans to shell out $24 per share for Ariad and its leukemia drug Iclusig and its late-stage ALK-inhibiting lung cancer drug brigatinib, now under priority...
More
